Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
© 2022 John Wiley & Sons Australia, Ltd..
BACKGROUND: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan-Meier analysis.
RESULTS: The PURPLE database included 754 cases with localised PDAC, including 148 (20%) cases with borderline resectable pancreatic cancer (BRPC). Of the 148 BRPC patients, 44 (30%) underwent immediate surgery, 80 (54%) received NA chemotherapy, and 24 (16%) were inoperable. The median age of NA therapy patients was 63 years and FOLFIRINOX (53%) was more often used as NA therapy than gemcitabine/nab-paclitaxel (31%). Patients who received FOLFIRINOX were younger than those who received gemcitabine/nab-paclitaxel (60 years vs. 67 years, p = .01). Surgery was performed in 54% (43 of 80) of BRPC patients receiving NA chemotherapy, with 53% (16 of 30) achieving R0 resections. BRPC patients undergoing surgery had a median OS of 30 months, and 38% (9 of 24) achieved R0 resection. NA chemotherapy patients had a median OS of 20 months, improving to 24 months versus 10 months for patients receiving FOLFIRINOX compared to gemcitabine/nab-paclitaxel (Hazard Ratio (HR) .3, p < .0001).
CONCLUSIONS: NA chemotherapy use in BRPC is increasing in Australia. One half of patients receiving NA chemotherapy proceed to curative resection, with 53% achieving R0 resections. Patients receiving Infusional 5-flurouracil, Irinotecan and Oxaliplatin (FOLIRINOX) had increased survival than gemcitabine/nab-paclitaxel. Treatment strategies are being explored in the MASTERPLAN and DYNAMIC-Pancreas trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Asia-Pacific journal of clinical oncology - 19(2023), 1 vom: 28. Feb., Seite 214-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walpole, Imogen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0W860991D6 |
|---|
| Anmerkungen: |
Date Completed 19.01.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajco.13807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343523205 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343523205 | ||
| 003 | DE-627 | ||
| 005 | 20231227130842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajco.13807 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM343523205 | ||
| 035 | |a (NLM)35831999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walpole, Imogen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan-Meier analysis | ||
| 520 | |a RESULTS: The PURPLE database included 754 cases with localised PDAC, including 148 (20%) cases with borderline resectable pancreatic cancer (BRPC). Of the 148 BRPC patients, 44 (30%) underwent immediate surgery, 80 (54%) received NA chemotherapy, and 24 (16%) were inoperable. The median age of NA therapy patients was 63 years and FOLFIRINOX (53%) was more often used as NA therapy than gemcitabine/nab-paclitaxel (31%). Patients who received FOLFIRINOX were younger than those who received gemcitabine/nab-paclitaxel (60 years vs. 67 years, p = .01). Surgery was performed in 54% (43 of 80) of BRPC patients receiving NA chemotherapy, with 53% (16 of 30) achieving R0 resections. BRPC patients undergoing surgery had a median OS of 30 months, and 38% (9 of 24) achieved R0 resection. NA chemotherapy patients had a median OS of 20 months, improving to 24 months versus 10 months for patients receiving FOLFIRINOX compared to gemcitabine/nab-paclitaxel (Hazard Ratio (HR) .3, p < .0001) | ||
| 520 | |a CONCLUSIONS: NA chemotherapy use in BRPC is increasing in Australia. One half of patients receiving NA chemotherapy proceed to curative resection, with 53% achieving R0 resections. Patients receiving Infusional 5-flurouracil, Irinotecan and Oxaliplatin (FOLIRINOX) had increased survival than gemcitabine/nab-paclitaxel. Treatment strategies are being explored in the MASTERPLAN and DYNAMIC-Pancreas trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a general surgery | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a neoadjuvant therapy | |
| 650 | 4 | |a pancreatic neoplasms | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 700 | 1 | |a Lee, Belinda |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Thomson, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Lipton, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Ananda, Sumitra |e verfasserin |4 aut | |
| 700 | 1 | |a Usatoff, Val |e verfasserin |4 aut | |
| 700 | 1 | |a Mclachlan, Sue-Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Knowles, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Cooray, Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Burge, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Pattison, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Nikfarjam, Mehrdad |e verfasserin |4 aut | |
| 700 | 1 | |a Tebbutt, Niall |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Nagrial, Adnan |e verfasserin |4 aut | |
| 700 | 1 | |a Zielinski, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Chee, Cheng Ean |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Asia-Pacific journal of clinical oncology |d 2010 |g 19(2023), 1 vom: 28. Feb., Seite 214-225 |w (DE-627)NLM197405231 |x 1743-7563 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:1 |g day:28 |g month:02 |g pages:214-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajco.13807 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 1 |b 28 |c 02 |h 214-225 | ||